Survival in MS A randomized cohort study 21 years after the start of the pivotal IFNβ-1b trial

Neurology

Volumn 78, Issue 17, 2012, Pages 1315-1322

  Goodin, D S ^a   Reder, A T ^b   Ebers, G C ^c   Cutter, G ^d   Kremenchutzky, M ^e   Oger, J ^f   Langdon, D ^g   Rametta, M ^h   Beckmann, K ⁱ   DeSimone, T M ^j   Knappertz, V ^h,k  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

^c JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^d UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^e LONDON HEALTH SCIENCES CENTRE   (Canada)

^f UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^g UNIVERSITY OF LONDON   (United Kingdom)

^h BAYER CORPORATION   (United States)

ⁱ BAYER PHARMA AG   (Germany)

^j PAREXEL INTERNATIONAL   (United States)

^k HEINRICH HEINE UNIVERSITY   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

INTERFERON BETA SERINE; PLACEBO;

ADULT; ARTICLE; CAUSE OF DEATH; COHORT ANALYSIS; CONTROLLED STUDY; EXPANDED DISABILITY STATUS SCALE; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; MULTIPLE SCLEROSIS; OUTCOME ASSESSMENT; PATIENT IDENTIFICATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE; TREATMENT DURATION; TREATMENT OUTCOME;

EID: 84860770990     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e3182535cf6     Document Type: Article

References (33)

1. Noseworthy JH, Luccinetti C, Rodriguez M, Weinshenker BG. Multiple Sclerosis. N Engl J Med 2000;343:938-952.
2. IFNB Multiple Sclerosis Study Group. Interferon β-1b is effective in relapsing-remitting multiple sclerosis. I: Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993;43:655-661.
3. Jacobs LD, Cookfair DL, Rudick RA, et al; The Multiple Sclerosis Collaborative Research Group (MSCRG). Intramuscular interferon β-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 1996;39:285-294. (Pubitemid 26100751)
4. PRISMS (Prevention of Relapses and Disability by Interferon β-1a Subcutaneously in Multiple Sclerosis) Study Group. Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis. Lancet 1998;352:1498-1504.
5. The Copolymer 1 Multiple Sclerosis Study Group. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: Results of a phase III multicenter, double-blind placebo-controlled trial. Neurology 1995;45:1268-1276.
6. Johnson KP, Brooks BR, Cohen JA, et al. Effect of early versus delayed interferon β-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: A 3-year follow-up analysis of the BENEFIT study. Lancet 2007;370:389-397.
7. European Study Group on Interferon β-1b in Secondary Progressive MS. Placebo-controlled multicentre randomised trial of interferon β-1b in treatment of secondary progressive multiple sclerosis. Lancet 1998;352:1491-1497.
8. Durelli L, Verdun E, Barbero P, et al. Every-other-day interferon β-1b versus once-weekly interferon β-1a for multiple sclerosis: Results of a 2-year prospective randomised multicentre study (INCOMIN). Lancet 2002; 359:1453-1460. (Pubitemid 34457761)
9. Rudge P. Are clinical trials of therapeutic agents for MS long enough? Lancet 1999;353:1033-1034. (Pubitemid 29149909)
10. Torkildsen GN, Lie SA, Aarseth JH, Nyland H, Myhr KM. Survival and cause of death in multiple sclerosis: Results from a 50-year follow-up in Western Norway. Mult Scler 2008;14:1191-1198.
11. Kingwell E, van der Kop M, Zhao Y, et al. Relative mortality and survival in multiple sclerosis: Findings from British Columbia, Canada. J Neurol Neurosurg Psychiatry. 2012; 83:61-66.
12. Wallin MT, Page WF, Kurtzke JF. Epidemiology of multiple sclerosis in US veterans. VIII: Long-term survival after onset of multiple sclerosis. Brain 2000;123:1677-1687. (Pubitemid 30481191)
13. Brønnum-Hansen H, Koch-Henriksen N, Stenager E. Trends in survival and cause of death in Danish patients with multiple sclerosis. Brain 2004;127:844-850. (Pubitemid 38478529)
14. Koch-Henriksen N, Brønnum-Hansen H, Stenager E. Underlying cause of death in Danish patients with multiple sclerosis: Results from the Danish Multiple Sclerosis Registry. J Neurol Neurosurg Psychiatry 1998;65:56-59. (Pubitemid 28302357)
15. Sumelahti M-L, Hakama M, Elovaara I, et al. Causes of death among patients with multiple sclerosis. Mult Scler 2010;16:1437-1442.
16. IFNB MS Study Group and UBC MS/MRI Study Group. Interferon β-1b in the treatment of MS: Final outcome of the randomized controlled trial. Neurology 1995;45: 1277-1285.
17. IFNB Multiple Sclerosis Study Group. Interferon β-1b is effective in relapsing-remitting multiple sclerosis. II: MRI analysis results of a multicenter, randomized, doubleblind, placebo-controlled trial. Neurology 1993;43:662-667.
18. Ebers GC, Traboulsee A, Li D, et al. Analysis of clinical outcomes according to original treatment groups 16 years after the pivotal IFNB-1b trial. J Neurol Neurosurg Psychiatry 2010;81:907-912.
19. Steyerberg EW, Rijkemans MJ, Harrell FR Jr., Habbema JD. Prognostic modelling with logistic regression analysis: A comparison of selection and estimation methods in small data sets. Stat Med 2000;19:1059-1079. (Pubitemid 30238915)
20. Weinshenker BG, Bass B, Rice GP, et al. The natural history of multiple sclerosis: A geographically based study. I: Clinical course and disability. Brain 1989;112:133-146. (Pubitemid 19056478)
21. Paty DW, Ebers GC. Multiple Sclerosis. Philadelphia: FA Davis Co; 1998.
22. Pocock SJ, Assmann SE, Enos LE, Kasten LE. Subgroup analysis, covariate adjustment and baseline comparisons in clinical trial reporting: Current practice and problems. Stat Med 2002;21:2917-2930.
23. Piantadosi S. Clinical Trials: A Methodologic Perspective, 2nd ed. Hoboken NJ: John Wiley & Sons; 2005.
24. Kappos L, Traboulsee A, Constantinescu C, et al. Long-term subcutaneous interferon β-1a therapy in patients with relapsing-remitting MS. Neurology 2006;67:944-953. (Pubitemid 44454583)
25. Bermel RA, Weinstock-Guttman B, Bourdette D, Foulds P, You X, Rudick RA. Intramuscular interferon β-1a therapy in patients with relapsing-remitting multiple sclerosis: A 15-year follow-up study. Mult Scler 2010; 16:588-596.
26. Ford C, Goodman AD, Johnson K, et al. Continuous long-term immunomodulatory therapy in relapsing multiple sclerosis: Results from the 15-year analysis of the US prospective open-label study of glatiramer acetate. Mult Scler 2010;16:342-350.
27. Bisson GP, Gaolathe T, Gross R, et al. Overestimates of survival after HAART: Implications for global scale-up efforts. PLoS One 2008;3:e1725.
28. Finkel T, Holbrook NJ. Oxidants, oxidative stress and the biology of ageing. Nature 2000;408:239-247.
29. Niizuma K, Endo H, Chan PH. Oxidative stress and mitochondrial dysfunction as determinants of ischemic neuronal death and survival. J Neurochem 2009;109(suppl 1): 133-138.
30. Sajad M, Zargan J, Chawla R, Umar S, Sadaqat M, Khan HA. Hippocampal neurodegeneration in experimental autoimmune encephalomyelitis (EAE): Potential role of inflammation activated myeloperoxidase. Mol Cell Biochem 2009;328:183-188.
31. Víctor VM, Espulgues JV, Hernández-Mijares A, Rocha M. Oxidative stress and mitochondrial dysfunction in sepsis: A potential therapy with mitochondria-targeted antioxidants. Infect Disord Drug Target 2009;9:376-389.
32. Cornwell WD, Kim V, Song C, Rogers TJ. Pathogenesis of inflammation and repair in advanced COPD. Semin Respir Crit Care Med 2010;31:257-266.
33. Croze E, Knappertz V, Yamaguchi K, et al. Integration of molecular mechanism studies and biological knowledge bases reveals the presence of a possible neuronal preservation process linked to mitochondrial dysfunction and oxidative stress in IFNB-1b-treated MS patients. Mult Scler 2010;16:S191-S192. Abstract P565.